Featured

While BioMarin and Spark remain out in front, Sangamo's data appear strong enough to warrant consideration of the biotech's therapy in the discussion of...

While Bristol-Myers executives successfully beat back Starboard and Wellington's efforts to derail the deal, the questions raised by that opposition remain. By buying Celgene, Bristol-Myers...

Takeda, on the cusp of closing its deal to acquire Shire, is also working to ramp up its efforts in emerging fields of cancer...

Investors reacted negatively to the pushed-back readouts, sending shares of the Singapore-based biotech down nearly 20% between Tuesday's market close and Wednesday's. Wall Street analysts,...

By most measures, Novartis enjoyed a positive start to 2019. Drug sales rose by 5% in dollar terms, lifted by strong performances from the Swiss...

Long known for its prowess in cardiovascular and respiratory diseases, AstraZeneca has joined its pharmaceutical peers in making a bigger play in oncology. While the...